CD19 and B-cell chronic lymphocytic leukemia: IL-18 secreting CD19 CAR-T demonstrated encouraging efficacy in an early clinical trials or the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) (NCT04684563) (172).